A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors

BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Adam L., Ray, Abhijit, Van Brocklin, Matthew, Burnett, David M., Bowen, Randy C., Dyess, Donna L., Butler, Thomas W., Dumlao, Theresa, Khong, Hung T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581038/
https://www.ncbi.nlm.nih.gov/pubmed/28881739
http://dx.doi.org/10.18632/oncotarget.14183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581038/
https://www.ncbi.nlm.nih.gov/pubmed/28881739
http://dx.doi.org/10.18632/oncotarget.14183

Ejemplares similares